At Diverse Biotech we are transforming the future of medicine by developing innovative, life-saving therapies for patients and healthcare professionals while delivering value to our investors.
Learn More
At Diverse Biotech we are dedicated to developing innovative medications that address critical unmet needs, providing hope and solutions for patients and healthcare professionals alike.
to transform lives through groundbreaking science. Our journey began with a commitment to challenge the status quo in drug development; we continue to innovate, collaborate, and push boundaries to deliver real impact where it's needed most.
Click and learn more
The pharmaceutical industry faces a critical challenge: innovation often comes from outside traditional giants. Diverse Biotech is utilizing its extensive USPTO issued intellectual property patents to fill this gap, driving discovery and development in areas of greatest need including, but not limited to, chemotherapeutic agents, cardiac medicines, anti-hypertensives, diabetes medicines, neurologics, neuroleptics, , non-steroidals, steroids, auto-immune therapies, arthritis (osteo, rheumatoid, psoriatic) therapies, ulcerative colitis therapies, hemophilia therapies, anti-protozoals, anti-virals, anti-helmintics, anti-protozoals, anti-psychotics, opthalmalogics, antibiotics, dermatologics, HIV therapies, and Hepatitis B and C therapies.
Click and learn more
Only 10 out of 44 new products (23%) from Pfizer were discovered and developed in-house in 2020. Click Here For Reference
For Johnson & Johnson, in 2020 just 2 of their 18 leading products (11%) were internally discovered, with 81% originating from innovative companies like Diverse Biotech. Click Here For Reference
Drug 1 and Drug 2 follow separate, uncoordinated pathways often failing to reach the same target locations.
This lack of precision combined with widespread toxicity leads to harmful effects throughout the body and limits clinical success.
With our innovative conjugate technology Drug 2 is released precisely at the site of Drug 1’s site of action ensuring both drugs are always present at the same location.
This targeted delivery dramatically reduces toxicity compared to Drug 1 and Drug 2 alone. The toxic effects are localized to the site of the cancer, sparing the rest of the body from harmful side effects.
Diverse Biotech, Inc., is not a “single-drug” or “single-disease” company.
Learn More